title: [Mesenchymal stem cells - The challenge of a good therapeutic product].
abstract: Mesenchymal stem cells (or stromal cells) have been initially characterized in bone marrow, but since, they have been identified in almost every tissue. Their multiple properties, namely differentiative capacity, production of cytokines and trophic molecules, and their immunosuppressive potential undoubtedly offer many therapeutic advantages, both for regenerative medecine or to relieve immune or inflammatory diseases. This is illustrated by the high number (> 100) of ongoing clinical trials with these cells. However, a prerequsite for their safe use in clinics is to guarantee that their production meet the good manufacturing practices, and that the final product is validated by adequate controls. It is thus quite a challenge to move from procedures defined for a research use to large scale production that fits with the national and international rules in terms of standardisation and controls. This underlines the importance of developping interacting networks between research teams, physicians and the industrial R&D departments. This fruitful collaboration will ensure the definition of appropriate and safe procedures for a successful therapeutic application.
authors: Établissement français du sang Pyrénées-Méditerranée, UMR5273 STROMALab-Inserm U1031, 75, rue de Lisieux, 31300 Toulouse, France. luc.sensebe@efs.sante.fr
authors: Luc
authors: L
authors: Sensebé
authors: Philippe
authors: P
authors: Bourin
mesh_terms: D018929:Cell Culture Techniques / Q000592:standards; D003470:Culture Media; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000592:standards*; D059630:Mesenchymal Stem Cells
chemical_list: D003470:Culture Media